FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity

BOTOX® is the First Neurotoxin Treatment Approved to Treat Pediatric Patients, 2 to 17 Years of Age, with Upper Limb Spasticity Approval Marks 10th BOTOX® Therapeutic Indication in its 30th Anniversary Year DUBLIN, June 21, 2019 -- (Healthcar... Biopharmaceuticals, FDA Allergan, BOTOX, onabotulinumtoxinA, limb spasticity

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2045129

Source: HSMN NewsFeed - June 21, 2019 Category: Pharmaceuticals Source Type: news